Scancell Holdings plc, the Oxford Science Park-based developer of novel immunotherapies for the treatment of cancer and infectious disease, has announced that a Phase 1 study on a next generation vaccine which could offer improved protection against new SARS-Cov-2 variants of concern (VoC) will begin in South Africa and the UK in the second half of this year, subject to local regulatory approvals.
The company has two next-generation Covid-19 vaccines in development which it hopes could offer improved protection against new SARS-Cov-2 variants of concern.
Last year the company entered into a collaboration with Cobra Biologics, part of the Cognate BioServices family, to conduct preliminary work leading to the manufacture of plasmids for Scancell’s COVID-19 vaccine.
Dr Cliff Holloway, Chief Executive Officer, Scancell, said: “There is a significant threat from future mutations of the SARS-CoV-2 virus, as we have seen with the rapid transmission of the Delta variant. Our next generation COVID-19 vaccine has the potential to work alongside currently approved vaccines by protecting the population against new variants of SARS-CoV-2. We look forward to initiating this trial in South Africa and the UK, and to updating the market in due course on further developments from the COVIDITY programme.”